We recently marked our official move to Frederick, MD with a ribbon cutting ceremony and celebration with our Cartesian colleagues, elected officials and the local Chamber. Exciting things ahead for Cartesian as we continue to build out our new facility, equipped with wholly-owned manufacturing capabilities and lab and office space. Thanks to everyone who joined in on the fun!
Cartesian Therapeutics
Biotechnology Research
Gaithersburg, MD 4,370 followers
Pioneering RNA cell therapy for autoimmune disease
About us
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Gaithersburg, MD
- Type
- Public Company
- Founded
- 2016
- Specialties
- Immunotherapy, Oncology, Molecular Biology, Immunology, Autoimmune Diseases, Myasthenia Gravis, ARDS, Cell Therapy, Lung disease, NETs, Cardiovascular Disease, Gene Therapy, Cancer Research, multiple myeloma, SLE, mRNA, and CAR-T
Locations
-
Primary
Gaithersburg, MD 20878, US
Employees at Cartesian Therapeutics
-
Christopher M. Jewell
Chief Scientific Officer, Cartesian Therapeutics | MPower Professor and Institute Professor of Translational Engineering | Biotechnology Consultant
-
Heng Xu
Research Scientist at Cartesian Therapeutics
-
Jessica Keliher, SPHR
Chief People Officer & Executive Leadership Coach
-
Carsten Brunn
President and CEO
Updates
-
Today, we are presenting at the Myasthenia Gravis Foundation of America, Inc. Scientific Session during the #AANEMAnnualMeeting, to highlight the potential of Cartesian’s lead cell therapy candidate, Descartes-08, for the treatment of #myastheniagravis. Full press release: https://bit.ly/405nFol
-
At the upcoming CAR-TCR Summit, management team members Milos Miljkovic, MD and Christopher M. Jewell, PhD are discussing the progress and opportunities of #celltherapy and the expanding potential in #autoimmune diseases. Details: https://bit.ly/47lHsBw
-
Today, we announced the receival of Rare Pediatric Disease Designation from the #FDA for #juveniledermatomyositis, underscoring our belief in the potential of Descartes-08 as a treatment of #autoimmunediseases. Learn more: https://bit.ly/3XAYzw0
-
Later this year, Cartesian’s CSO Christopher M. Jewell will present at the Cell Therapy Autoimmune Summit. Chris will discuss the unique challenges of cell therapies in the #autoimmune space, and how Cartesian is addressing them through the development of differentiated mRNA therapies. More details here: https://bit.ly/46HNsEy
Program Director at Hanson Wade | 6th TIL Therapies Summit 2024 | 2nd Cell Therapies for Autoimmune Disease Summit 2024 | 10th Innate Killer Summit 2025 | 7th Allogeneic Cell Therapies Summit 2025
“It’s amazing to have a group of experts and different stakeholders come together at the 2nd Cell Therapy for Autoimmune Disease Summit to focus on this topic. It’s a great networking opportunity to connect with people to understand where the field is and what the challenges are’’ I recently had an exciting conversation with Christopher M. Jewell, the Chief Scientific Officer at Cartesian Therapeutics. We dove into the explosive growth of the field, its bright future, the challenges on the horizon, and the innovative work being driven by Cartesian. The full conversation is available to watch here: https://ter.li/0arlu6
-
At two upcoming investor conferences, our management team will discuss upcoming milestones and how we are leveraging the power of #celltherapy for patients with #autoimmunediseases. Information here: https://bit.ly/46ZxSEc
-
Join us at next week’s Cell & Gene Live event discussing modernizing CAR-T manufacturing, where Cartesian’s Emily English will speak about the challenges, opportunities, and future of CAR-T cell therapies. Register here: https://bit.ly/4cn8Lwc
-
Today we reported second quarter 2024 financial results and provided a business update. Full press release: https://bit.ly/4dSMd7Z #celltherapy #autoimmunity
-
Tune in today to hear from Emily English on mRNA quality guidelines and how Cartesian is applying these to our pipeline of mRNA cell therapy programs for #autoimmune diseases. Register here: https://bit.ly/3y6O4qx